198 related articles for article (PubMed ID: 38563421)
1. Nanomedicine Remodels Tumor Microenvironment for Solid Tumor Immunotherapy.
Guo Y; Hu P; Shi J
J Am Chem Soc; 2024 Apr; 146(15):10217-10233. PubMed ID: 38563421
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
3. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
4. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
[TBL] [Abstract][Full Text] [Related]
5. Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by modulating immunosuppressive tumor microenvironment.
Sun K; Yu J; Hu J; Chen J; Song J; Chen Z; Cai Z; Lu Z; Zhang L; Wang Z
Acta Biomater; 2022 Aug; 148():230-243. PubMed ID: 35724919
[TBL] [Abstract][Full Text] [Related]
6. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
Sun B; Hyun H; Li LT; Wang AZ
Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma.
Pan X; Ni S; Hu K
Biomaterials; 2024 Apr; 306():122481. PubMed ID: 38286109
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
9. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
Cho H; Kim K
Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
[TBL] [Abstract][Full Text] [Related]
10. Stimuli-Sheddable Nanomedicine Overcoming Pathophysiological Barriers for Potentiating Immunotherapy of Cancer.
Wang J; Zhou M; Chen F; Liu X; Gao J; Wang W; Wang H; Yu H
J Biomed Nanotechnol; 2021 Aug; 17(8):1486-1509. PubMed ID: 34544528
[TBL] [Abstract][Full Text] [Related]
11. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.
Yang Y; Zhao T; Chen Q; Li Y; Xiao Z; Xiang Y; Wang B; Qiu Y; Tu S; Jiang Y; Nan Y; Huang Q; Ai K
Adv Sci (Weinh); 2022 Oct; 9(28):e2202797. PubMed ID: 35869032
[TBL] [Abstract][Full Text] [Related]
13. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy.
Abdelgalil RM; Elmorshedy YM; Elkhodairy KA; Teleb M; Bekhit AA; Khattab SN; Elzoghby AO
Nanomedicine (Lond); 2022 Sep; 17(22):1721-1745. PubMed ID: 36621872
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.
Ji B; Wei M; Yang B
Theranostics; 2022; 12(1):434-458. PubMed ID: 34987658
[TBL] [Abstract][Full Text] [Related]
15. Physical oncology: New targets for nanomedicine.
Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
[TBL] [Abstract][Full Text] [Related]
16. Remodeling tumor microenvironment with nanomedicines.
Martin JD; Miyazaki T; Cabral H
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1730. PubMed ID: 34124849
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine Targeting Myeloid-Derived Suppressor Cells Enhances Anti-Tumor Immunity.
Yang EL; Sun ZJ
Adv Healthc Mater; 2024 Apr; 13(9):e2303294. PubMed ID: 38288864
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages.
Li X; Guo X; Ling J; Tang Z; Huang G; He L; Chen T
Nanoscale; 2021 Mar; 13(9):4705-4727. PubMed ID: 33625411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
